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DNA repair deficiency biomarkers and the 70-gene ultra-high
risk signature as predictors of veliparib/carboplatin response in
the I-SPY 2 breast cancer trial
Denise M. Wolf1, Christina Yau2, Ashish Sanil3, Annuska Glas4, Emanuel Petricoin5, Julia Wulfkuhle5, Tesa M. Severson6, Sabine Linn6,
Lamorna Brown-Swigart1, Gillian Hirst 2, Meredith Buxton7, Angela DeMichele8, Nola Hylton9, Fraser Symmans10, Doug Yee11,
Melissa Paoloni7, Laura Esserman2, Don Berry3, Hope Rugo12, Olufunmilayo Olopade13 and Laura van ‘t Veer1
Veliparib combined with carboplatin (VC) was an experimental regimen evaluated in the biomarker-rich neoadjuvant I-SPY 2 trial for
breast cancer. VC showed improved efficacy in the triple negative signature. However, not all triple negative patients achieved
pathologic complete response and some HR+HER2− patients responded. Pre-specified analysis of five DNA repair deficiency
biomarkers (BRCA1/2 germline mutation; PARPi-7, BRCA1ness, and CIN70 expression signatures; and PARP1 protein) was performed
on 116 HER2− patients (VC: 72 and concurrent controls: 44). We also evaluated the 70-gene ultra-high risk signature (MP1/2), one of
the biomarkers used to define subtype in the trial. We used logistic modeling to assess biomarker performance. Successful
biomarkers were combined using a simple voting scheme to refine the ‘predicted sensitive’ group and Bayesian modeling used to
estimate the pathologic complete response rates. BRCA1/2 germline mutation status associated with VC response, but its low
prevalence precluded further evaluation. PARPi-7, BRCA1ness, and MP1/2 specifically associated with response in the VC arm but
not the control arm. Neither CIN70 nor PARP1 protein specifically predicted VC response. When we combined the PARPi-7 and MP1/
2 classifications, the 42% of triple negative patients who were PARPi7-high and MP2 had an estimated pCR rate of 75% in the VC
arm. Only 11% of HR+/HER2− patients were PARPi7-high and MP2; but these patients were also more responsive to VC with
estimated pathologic complete response rates of 41%. PARPi-7, BRCA1ness and MP1/2 signatures may help refine predictions of VC
response, thereby improving patient care.
npj Breast Cancer  (2017) 3:31 ; doi:10.1038/s41523-017-0025-7
INTRODUCTION
Poly(ADP-ribose) polymerase (PARP) inhibitors belong to an
emerging class of drugs that operate on the principle known as
‘synthetic lethality’.1, 2 PARP is involved in single strand break (SSB)
DNA repair; and upon PARP inhibition, some SSBs are converted
into double strand breaks (DSBs) at replication forks. In homo-
logous repair competent cells, DSBs are repaired so that the cells
can survive.3 However, in homologous repair-deficient cells, DSBs
are repaired via the less accurate non-homologous end joining
pathway or by single strand annealing, resulting in aberrant
chromatids that trigger cell death.4 Thus, cells with BRCA
mutations or other homologous repair defects5–7 are preferentially
sensitive to PARP inhibitors.
The PARP inhibitor, olaparib, was recently FDA approved for
BRCA1/2 mutation positive patients with advanced ovarian cancer.
There are at least five PARP inhibitors under clinical investigation,
including olaparib (AstraZeneca, London), veliparib (ABT-888;
Abbott Laboratories, IL), rucaparib (AG014699; Clovis Oncology),
niraparib (MK4827; Merck), and talazoparib (BMN673; Medivation,
CA)8–15 for BRCA-associated, triple negative (TN) and/or basal
breast cancers and other solid tumors, either as monotherapy in
DNA repair deficient patients or as potentiating agents for
radiation or DNA-damaging anticancer agents.16–18 Results from
clinical trials in breast cancer in the advanced disease setting
appear to vary depending on patient characteristics and the
therapeutic regimen under investigation.19 Phase 2 trials showed
that olaparib as monotherapy led to objective response rates in
31–41% of BRCA1/2 mutation carriers who had previously
received several courses of chemotherapy.14, 20, 21 However,
results for BRCA1/2 wild-type breast cancer patients have been
inconsistent. TN breast cancer patients without BRCA mutations
largely did not respond to olaparib monotherapy in a phase 2
trial,22 whereas preclinical studies and phase 1 trials suggested
that PARP inhibitors can be efficacious in these patients when
combined with DNA damaging cytotoxic agents.17
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Veliparib in combination with carboplatin (VC) was recently
evaluated in I-SPY 2, a multi-center Phase 2 adaptive standing
platform trial for women with early stage, locally advanced,
aggressive breast cancer.23 I-SPY 2 is designed to screen multiple
experimental regimens in addition to standard neoadjuvant
chemotherapy (Fig. 1a). Women with HER2+ disease also receive
trastuzumab or other HER2-targeted therapy. This trial is adaptive,
in that a patient randomized to receive experimental treatment is
assigned preferentially to the arm where her cancer subtype is
most likely to respond. Subtype is defined by hormone receptor
(HR) status, HER2 status, and MammaPrint (MP) High 1/High 2 risk
status (MP1/2), essentially a further stratification of the MP poor
prognosis group (MP High) into high and ultra-high risk groups.
The primary endpoint is pathologic complete response (pCR), i.e.,
no invasive cancer left in the breast or lymph nodes. The goal of
I-SPY 2 is to identify (graduate) regimens with >85% predicted
probability of succeeding in a 1:1 randomized 300-patient phase 3
trial where pCR is the endpoint, in the signatures defined by HR,
HER2, and MP where the drug is most effective (graduates). The
VC arm was open for enrollment to HER2-negative (HER2−)
patients, and VC was eligible for graduation in three signatures:
HER2-negative, HR-positive HER2-negative (HR+HER2−), and TN.
VC successfully graduated in the TN signature;23 but not all TN
patients in the VC arm achieved a pCR, and many outside this
subset responded. There is a need for additional robust
biomarkers that predict VC sensitivity. Just as the I-SPY 2 standing
platform trial is an efficient mechanism for screening promising
agents for Phase 3 testing, the biomarker component of I-SPY 2,
where samples are profiled for gene expression, protein levels and
mutation status, provides a centralized resource for investigators
to propose and test additional mechanism-of-action-based
biomarkers using a rigorous, pre-defined analysis methodology
in the context of the established clinically relevant biomarkers
already incorporated within the trial. Previous studies have
proposed homologous DNA repair deficiency (HRD) biomarkers,
such as BRCA1/2 mutation,24, 25 BRCA1 promoter methylation,26–28
‘BRCAness’ expression and CGH signatures,27, 29 Fanconi F and D
methylation or loss,30 p53 and PTEN loss of function mutations or
expression level,31–33 cell line based HRD/PARPi signatures,34
telomeric allelic imbalance,35 loss of heterozygocity HRD scoring,36
and HRD ‘genomic scarring’,37 among others,27, 38, 39 as possible
markers of sensitivity to PARP inhibition. Through the I-SPY 2 Data
access and Publication Committee process, five investigator-
submitted qualifying biomarker concept proposals related to DNA
damage repair deficiency were approved and individually
evaluated in baseline (pre-treatment) biopsies as specific biomar-
kers of VC response.
The five proposed mechanism-of-action-based biomarkers
were: (1) BRCA1/BRCA2 germline mutation; (2) a 7-gene DNA-
repair deficiency expression signature (PARPi-7) that predicts
breast cancer cell line sensitivity to the PARP inhibitor olaparib; 34
(3) a 77-gene BRCA1ness expression signature;40, 41 (4) the CIN70
chromosomal instability expression signature;42, 43 and (5) PARP1
protein levels, the target of veliparib. In addition, we also consider
MP1/2 status, because the restricted enrollment of the VC arm to
HER2− patients precluded the MP2 signature from being eligible
for graduation. In this report, we present our evaluation of the
predictive performance of each of these six biomarkers in the VC
arm relative to the control arm, analyzed in isolation and in the
context of the graduating TN subset. In addition, we compare
these biomarkers to determine whether they are identifying the
same patients, and perform an exploratory analysis that combines
the most successful candidates into a composite VC sensitivity
score.
RESULTS
Patient characteristics summary
A total of 72 patients were randomized to the VC arm, and treated
with veliparib and carboplatin in addition to standard taxane/
anthracycline chemotherapy (VC+T−>AC). There were 44 concur-
rently randomized HER2− controls treated with standard che-
motherapy (T−>AC).23 Patients who received non-protocol
therapy, left their treating institution, or withdrew consent prior
to surgery were considered non-pCR as per protocol. Patient and
baseline clinical characteristics, such as age, ethnicity, HR status,
tumor size and nodal status, were similar between the experi-
mental and control arms.23 All 116 patients have Agilent 44 K
expression arrays available. 98% of patients (n = 114) were
evaluated for BRCA germline mutation status; and 89% (n = 103)
have available RPPA data (Fig. 1b).
BRCA1/2 germline mutation status
Of the 114 patients evaluated for BRCA1/2 germline mutation
status, 15 were found to carry a deleterious or suspected
deleterious BRCA1/2 mutation, with the majority (n = 11) occurring
within the TN subtype. In the VC arm, BRCA mutation carriers were
Fig. 1 a I-SPY 2 TRIAL design schematic. Only patients with HER2− disease were eligible for randomization to the VC arm. b Consort diagram
for the VC arm and HER2− concurrent controls, showing data availability for biomarker analysis
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more likely to achieve a pCR compared to wild-type patients
(75 vs. 29%) (Fig. S1). This translates to an odds ratio of 7.25
between the BRCA1/2 germline mutation carriers and wildtype
patients (Fisher Exact test p-value = 0.006, Table 1). The small
number of mutation carriers in the control arm (n = 3) precluded
further evaluation.
The PARPi-7 and BRCA1ness signatures and MP1/2 classification
specifically predict VC response
We evaluated as proposed three dichotomous expression based
signatures—the BRCA1ness signature, the CIN70 signature and
the MP1/2 risk classification—and one continuous signature
(PARPi-7) as qualifying biomarkers of VC response using our
predefined qualifying biomarker evaluation (QBE) process
(see Fig. 2).
The PARPi-7 and BRCA1ness signatures and the MP1/2 risk
classification associated with response in the VC arm (p < 0.05),
but not the control arm (Table 1). Using logistic regression, for
each of these three signatures, the biomarker x treatment
interaction term reflecting the relative biomarker performance
between arms had a likelihood ratio (LR) test p value of <0.05,
which remains significant (LR p < 0.05) upon adjusting for receptor
subtype (Table 1).
Neither the CIN70 signature nor the total and cleaved PARP
protein levels succeeded as specific biomarkers of response to VC
(Table 1 and Fig. S2).
For potential clinical utility and ease of comparison to the other
successful signatures, we dichotomize the patients using the
PARPi-7 signature at the published threshold (0.0372)34 [see Fig.
S3] and use the dichotomous version of this signature henceforth.
Figure 3a shows the biomarker signature prevalence and
composition in the VC and control arms. pCR rates by receptor
subtype, treatment arm, and biomarker are shown in Fig. S4. As
shown in the mosaic plots in Fig. 3b–d, PARPi-7 High, BRCA1ness
and MP2 patients all had a higher pCR rate in the VC arm (Fisher’s
exact test p < 0.05), but not the control arm (p > 0.05), when
compared to biomarker-negative patients.
We used Bayesian modeling, similar to the I-SPY 2 primary
efficacy analysis, to estimate the pCR probabilities to VC and
standard chemotherapy in biomarker predicted-sensitive patient
subsets (PARPi-7 High, BRCA-like, and MP2). As shown in Fig. 3e–g,
estimated pCR probabilities in the VC arm range from 50–61% vs.
18–27% in the control arm, in these subsets. We also computed
the predictive probability of VC demonstrating superiority to
control in a 1:1 randomized neoadjuvant phase 3 trial of 300
biomarker predicted-sensitive patients. These probabilities are
>90% (95% for PARPi-7 High, 96% for BRCA1ness and 94% for MP2
patients). If we exclude the 15 BRCA1/2 germline mutation carriers
from the analysis and consider only BRCA1/2 wild-type patients,
these probabilities are 75% for PARPi-7 High, 81% for BRCA1ness
and 87% for MP2 patients.
Expanding the ‘predicted-responder’ group beyond TN using
qualifying biomarkers
We evaluated the PARPi-7, BRCA1ness and MP1/2 signatures in
relation to the graduating TN signature, by adding biomarker-
positive HR+/HER2− patients to the TN group and evaluating
whether the treatment effect of VC remains significant in this
expanded population of ‘predicted sensitive’ patients. For all three
signatures, the VC treatment effect in the expanded population
remains similar to that observed within the graduating TN
signature (see Table S2 for details); and the predicted probability
of success in phase 3 in these expanded groups are comparable to
the graduating signature (Fig. S5). For instance, if the PARPi-7 is
used to expand the population by adding PARPi-7 High HR+HER2−
patients to the TN group, the probability of VC demonstrating
superiority to control in phase 3 is 90%, while increasing theT
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prevalence of ‘predicted sensitive’ patients by 23% of HR+/HER2−
patients in the trial. Similar results were observed when the
BRCA1ness and MP1/2 signatures were considered (Fig. S5).
Comparing and combining qualifying biomarkers in the context of
HR and HER2 status to improve response prediction
Since PARPi-7, BRCA1ness, and MP1/2 all appear to succeed as
specific predictors of VC combination therapy in I-SPY 2, we
wondered whether these signatures identify the same patients,
and if not, whether individual biomarkers could be combined to
better identify likely responders within the TN and HR+/HER2−
subsets. As shown in Fig. 3a, the concordance between biomarker
pairs over all patients in the trial ranges from 66–78%, indicating
that these biomarkers are not identifying exactly the same
patients.
In our exploratory analysis that was not pre-specified, we
combined pairs of biomarkers using a simple voting scheme. As
shown in Fig. 4a, if patients are classified as resistant by both
biomarkers, or resistant by one biomarker, they are classified as
‘resistant’. Patients are classified as ‘sensitive’ only if both
biomarkers are in the ‘sensitive’ state.
Biomarker combinations within the TN subtype. Though 95%
(57/60) of TN patients are PARPi7-high or MP2 or BRCA1ness,
only 38% would be classified as sensitive by all three biomarkers
(Fig. 4b).
Figure 4c shows the pCR probability distributions of TN patients
in the VC and control arms, with estimated pCR rates of 51% in the
VC arm and 26% in the control arm. In TN patients predicted VC-
sensitive by a single additional biomarker, there is a greater
separation in the pCR probability distributions between arms, with
estimated pCR rates to VC ranging from 56% to 70% (Fig. 4d–f). If
we combine the two biomarkers yielding the highest estimated
pCR rate in the VC arm (PARPi-7 and MP2) to select TN patients
who are TN/MP2/PARPi7-high (Fig. 4g), the separation of the
estimated pCR rates between arms is greater still (75% in VC vs.
23% in control), with a predictive probability of success in phase 3
of 99% (Table S3). This group constitutes a sizeable 42% of TN
patients in the trial (Fig. 4h). In contrast, the pCR probability
distributions of TN patients with one or more markers in the
resistant state (TN/PARPi7-low or TN/MP1) are nearly overlapping
(Fig. 4i).
If we exclude the BRCA1/2 germline mutation carriers from the
analysis, the separation of estimated pCR rates between arms is
still large in the TN/MP2/PARPi7-high group (63% in VC vs. 23% in
control), with a predictive probability of success in phase 3 of 95%
(Fig. S6).
Biomarker combinations within the HR+/HER2− subtype. Only
34% (19/56) of HR+/HER2− patients are positive for one or more
VC sensitivity biomarkers. 23% (13/56) are PARPi7-high, 20% (11/
56) are MP2, and 14% (8/56) are BRCA1ness (Fig. 5a).
HR+/HER2− patients had low estimated pCR rates in both arms
with nearly overlapping probability distributions (estimated pCR:
15% in VC, 19% in control; Fig. 5b). In HR+HER2− patients predicted
VC sensitive by a single additional biomarker, there is a greater
separation in the pCR probability distributions between arms with
estimated pCR rates to VC of 33% in the HR+HER2−/MP2 and HR
+HER2−/PARPi7-High subsets (Fig. 5c–e). If we combine MP1/2 and
PARPi-7 per above to select HR+HER2− patients who are HR+HER2-/
MP2/PARPi7-high (Fig. 5f), the separation of the estimated pCR rates
between arms increases further (41% in VC vs. 15% in control), with
a predictive probability of success in phase 3 of 82% (Fig. 5f; Table
S3). In contrast, HR+/HER2− patients negative for at least one VC
sensitivity marker (HR+HER2−/PARPi7-low, or HR+HER2-/MP1) have
nearly overlapping pCR probability distributions with estimated pCR
rates of 13% in VC vs. 19% in controls (Fig. 5g).
Fig. 2 Biomarker analysis approach. Qualifying biomarker candidates are evaluated as specific predictors of response to VC using a predefined
3-step Qualifying Biomarker Evaluation (QBE) methodology, as shown in this flow diagram
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Although our results demonstrate that ‘double biomarker-
positive’ in both TN and HR+HER2− patients may be more sensitive
to VC than patients with fewer markers in the ‘sensitive’ state, the
prevalence of MP2/PARPi7-high patients in the TN subset is
relatively high (42%; Fig. 4i), whereas HR+/HER2− patients with
these markers are relatively rare (11%; Fig. 5h).
DISCUSSION
The I-SPY 2 TRIAL design presents both opportunities and
challenges for evidence-based biomarker testing. On one hand,
the biomarker-rich nature of the trial, in which pre-treatment
tumor biopsies are assayed on Agilent 44 K expression and RPPA
protein/phospho-protein platforms, provides an excellent
resource to investigate the molecular correlates of response and
resistance. As well, collection of serial biopsies and blood samples
over the course of therapy generates an invaluable repository for
additional molecular profiling.
On the other hand, as the I-SPY 2 TRIAL was designed to
efficiently evaluate multiple novel regimens compared to a shared
control arm for future Phase 3 testing, the sample sizes available
for our biomarker studies are small. As well, VC is given as a
combination therapy within the I-SPY 2 trial. While assessing the
relative performance of a biomarker in the experimental vs.
control arms enables us to identify specific predictors of response
to VC, it is impossible to assess whether the successful biomarkers
described in our report are predictive of response to the individual
agents within the combination. In addition, I-SPY 2 uses adaptive
randomization within HR/HER2/MP defined subtypes to enable
efficient matching of novel regimens with their most responsive
clinically relevant signatures. This may result in the unbalanced
prevalence of biomarker-positive subsets in the experimental and
control arms if the biomarker of interest is correlated with a HR/
HER2/MP subtype that is preferentially enriched or depleted in the
experimental arm by the randomization engine. As well, there are
multiple genes in each signature measured on several platforms,
creating the problem of multiplicity, which is compounded by the
evaluation of multiple proposals. Altogether, these challenges
limit our ability to draw definitive conclusions. Thus, our statistics
are descriptive rather than inferential; and our findings require
further validation in future trials.
Four of the five evidence-based, mechanism-of-action related
(qualifying) biomarkers included in this report are markers of DNA
repair deficiency because of the large body of in vitro and in vivo
evidence that DNA repair deficient cancers selectively respond to
DNA damaging agents potentiated by PARP inhibition. Many
studies support BRCA1/2 germline mutation status as the ‘gold
standard’ biomarker for predicting sensitivity to PARP inhibitors as
Fig. 3 Qualifying biomarker performance. a Ordered heatmap showing the prevalence of all dichotomized biomarkers evaluated in this study,
stratified by HR status. b–d Mosaic plots showing patient response stratified by treatment arm and b PARPi-7, c BRCA1ness (this figure panel is
also jointly published in ref. [41]), and d MP1/2 signatures, respectively. e–g Bayesian estimated pCR probability distributions by treatment
arm, for e PARPi7-high, f BRCA1ness, and g MP2 patients
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monotherapy. In I-SPY 2, BRCA1/2 mutation carriers were indeed
more likely to respond to VC than BRCA1/2 wildtype patients, but
the mutation prevalence was too low for a comparison to
response in the control arm.
Of the three DNA repair based expression signatures we
evaluated, two (PARPi7 and BRCA1ness) were associated with
response in the VC arm, but not in the control arm, and had a
significant biomarker x treatment interaction that retained
significance upon adjusting for HR status. These two successful
qualifying biomarker signatures were derived in very different
ways. The PARPi-7 signature was the result of an effort to build a
predictor of response to a different PARP inhibitor, olaparib, using
a breast cancer cell line panel and a candidate gene set restricted
to DNA repair genes in one of the six major repair pathways. The
BRCA1ness signature, on the other hand, was developed as a
classifier to identify cancers exhibiting a BRCA1-mutated copy
number profile. Indeed, 80% (12/15) of BRCA+ patients were
classified as BRCA1ness, along with many non-mutation carriers.
Interestingly, the concordance between these signatures is only
moderate, and while both BRCA1ness and PARPi7 have predictive
signal, the nature of this signal differs. In the TN subset, the
differential response in the VC and control arms in BRCA1ness
cancers mostly manifests as a depletion of responders in the
control arm rather than an increase in responders in the VC arm
relative to unselected TNs. Whereas the difference in estimated
pCR rates in VC vs. control for PARPi7-high patients is driven by a
higher response rate in VC.
Neither the PARP1 protein levels nor the dichotomized
CIN70 signature specifically predict response to VC. The lack of
association observed between PARP1 protein levels and differ-
ential response has been seen elsewhere in PARP inhibitor trials,
perhaps due to saturation properties of the antibody or to a
disconnect between DNA repair deficiency and PARP1 levels as
measured. For CIN70, the lack of association with response may be
due to the small size of the population or a non-ideal quantile
cutoff for dichotomizing the I-SPY 2 patients, as it associates with
response as a continuous variable.
We did not test non-expression based HRD biomarkers found to
associate with response to platinum-based DNA damaging agents,
including the HRD-LOH/HRD-LST score or Myriad’s HRD test
quantifying the level of ‘DNA scarring’ on tumor genomes.36, 37 As
these measures are in a sense closer to a direct read-out of DNA
repair deficiency, it may be interesting to examine their correlation
to the expression-based biomarkers we evaluated and to compare
their predictive performance in I-SPY 2. But tissue availability is
limited; and careful consideration is needed in determining the
optimal use of samples within the I-SPY 2 tissue repository.
Our analysis suggests that had HER2−/MP2 or TN/
MP2 signatures been eligible for graduation of VC from the I-
SPY 2 trial, they would have graduated along with the TN
signature (with >85% predictive probability of success in phase 3).
Though not explicitly developed as a DNA repair deficiency
biomarker, preliminary analysis of pathway differences between
MP1 and MP2 class tumors suggest that MP2 cancers have higher
expression of cell cycle genes and DNA repair pathways other
than homologous repair.44 This may explain why MP1/2 and
PARPi-7 are not highly concordant, as the latter largely reflects
HRD.
Fig. 4 Combining VC-sensitivity markers in TN patients. a Simple voting scheme for combining biomarkers to refine sensitivity prediction. b
Venn diagram showing overlap between VC-sensitivity biomarkers, including the graduating TN signature. c–f Bayesian estimated pCR
probability distributions by treatment arm, for c unselected triple negative [TN], d TN/MP2, e TN/PARPi7-high, and f TN/BRCA1ness patients,
respectively. g, h Bayesian estimated pCR probability distributions by treatment arm, for g predicted sensitive (TN/MP2/PARPi7-high) and h
predicted resistant (TN/(MP1 or PARPi7-low)) triple negative patients. i Pie chart showing relative proportion of predicted sensitive vs. resistant
TN patients
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The biomarker component of I-SPY 2 must function in the
context of I-SPY 2’s innovative adaptive trial design. VC graduated
with a >85% probability of success in a future phase 3 trial,
conducted not in the general breast cancer population, but in the
TN subset. Thus, TN (HR−/HER2−) status is already a successful
biomarker for VC, and we must try to understand how the novel
mechanism-of-action based biomarkers we are testing add value
to the graduating TN signature. To this end, we imagined two
different purposes for a biomarker.
One purpose of a biomarker concerns clinical decision making for
individual patients, also known as personalized oncology. For this
application, the objective is to use all the available information to
predict the likelihood of an individual patient’s response to a set of
treatment options. For this type of analysis we combine successful
biomarkers, such as the qualifying biomarkers and the graduating
signature to refine the sensitivity prediction. For instance, we
combine TN status with the PARPi-7 signature, to show that TN
patients who are also PARPi7-high have a 70% probability of
achieving pCR in the VC arm compared to 30% in the control arm.
We also show how a simple voting method can be used to combine
information from multiple sensitivity biomarkers (PARPi7 and MP2)
to improve VC response prediction to 75% pCR probability.
Moreover, MP2/PARPi7-high remains a strong predictor of response
to VC relative to control in TN patients who are BRCA1/2 wild-type.
This information would be useful for a patient selecting a treatment
protocol, but may not be appropriate for patient selection in a trial
because the improved performance of the biomarker comes at the
expense of excluding a large segment of the TN population.
Another purpose is to use the novel biomarker together with
the graduating group to improve patient selection in a future
phase 3 trial of VC. In this setting, an ideal biomarker is one which
identifies the maximum number of patients likely to have a
sufficiently improved response to VC (relative to control) so as to
succeed in a subsequent phase 3 trial conducted in this
‘biomarker-positive’ group. Maximizing the size of this
biomarker-positive subset is desirable because phase 3 testing
and thus approval of VC will likely be limited to this group. When
we added single biomarker positive HR+HER2− patients to the
graduating TN group, the Bayesian probabilities of success in
phase 3 of this expanded biomarker-positive population is similar
to the graduating TN signature, while increasing prevalence by
adding 14–23%. Using the voting method, only 11% of HR+HER2−
patients would be added to the predicted responder group. This
example illustrates a generic trade-off between biomarker
performance and prevalence (or specificity and sensitivity), with
‘fit for purpose’ implications for how these biomarkers are best
used combinatorially.
Our future plans include evaluating whether the biomarkers
predictive of VC response in the I-SPY 2 TRIAL can also predict
sensitivity to other PARP inhibitors combined with DNA damaging
agents or even carboplatin alone. In addition, we plan to use these
biomarkers as part of a SMART-trial design to adapt treatment
within patients who are not responding to their initial therapy.
METHODS
In the I-SPY 2 TRIAL (NCT01042379), HER2− patients were randomized to
receive standard chemotherapy (paclitaxel followed by doxorubicin/
cyclophosphamide; T−>AC) or the oral PARP inhibitor veliparib in
combination with carboplatin and chemotherapy (VC+T−>AC).23 Pre-
treatment samples from patients in the veliparib/carboplatin (VC) and
concurrent control arms of the I-SPY 2 trial23 were profiled using Agilent
44 K expression arrays (Agendia, Inc) and reverse phase protein arrays
(RPPA). Details of the sample preparation and data processing are provided
in the Supplemental Methods. In addition, BRCA1/2 mutation status was
assessed (Myriad Genetics Laboratories).
We evaluated six biomarkers as specific predictors of VC response using
a pre-specified QBE methodology. Briefly, we follow a three-step
methodology, first evaluating the relative performance of the biomarker
between arms, followed by assessing biomarker performance in the
Fig. 5 Combining VC-sensitivity markers in HR+HER2− patients. a Venn diagram showing overlap between VC-sensitivity biomarkers in the HR
+HER2− subset. b–g Bayesian estimated pCR probability distributions by treatment arm, for b unselected HR+HER2−, c HR+HER2−/MP2, d HR
+HER2−/PARPi7-high, and e HR+HER2−/BRCA1ness patients, respectively, and for HR+HER2− patients who are f predicted sensitive (HR+HER2
−/MP2/PARPi7-high) and g predicted resistant (HR+HER2−/(MP1 or PARPi7-low)) by our simple voting scheme. h Pie chart showing relative
proportion of predicted sensitive vs. resistant HR+HER2− patients
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context of the graduating (TN) signature. Finally, we perform Bayesian
analysis to estimate pCR rates in the arms and the predictive probability of
VC showing superiority to control in biomarker defined subsets. The six
biomarkers evaluated are: (1) BRCA germline mutation; (2) a 7-gene DNA-
repair deficiency expression signature (PARPi-7)34; (3) a 77-gene BRCA1ness
expression signature;40, 41 (4) the CIN70 chromosomal instability expres-
sion signature;42, 43 (5) PARP1 protein levels; and (6) MP1/2 status. Details
of the definition and scoring of each biomarker and our evaluation
methodology are available in the Supplemental Methods. Each individual
biomarker was evaluated separately; and these analyses did not account
for multiplicities outside of the study.
In an exploratory analysis, we evaluate the concordance between
successful biomarkers using the Kappa statistic. We use a simple voting
method to combine the two most successful VC-sensitivity biomarkers and
use Bayesian modeling to estimate the pCR rates and predictive probability
of phase 3 trial success of biomarker-positive TN and HR+HER2− patients.
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